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Immunotherapy	  against	  cancer	  
Conven5onal	  cancer	  therapies:	  
•  Not	  specific:	  tumor	  and	  healthy	  5ssue	  are	  affected;	  
•  Not	  effec5ve	  for	  all	  pa5ents;	  
•  Collateral	  effects;	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Our	  CAR-­‐T	  cells	  specifically	  detect	  B	  cells	  and	  lead	  
to	  cell	  death	  within	  24	  hours	  of	  co-­‐cul5va5on.	  
	  
•  Next	  Steps	  
	  -­‐Finalize	  the	  bioprocess	  of	  CAR-­‐t	  cell	  expansion	  	  
	  -­‐Ini5ate	  the	  in	  vivo	  experiments	  
	  
